Thiazoles
Medchemexpress LLC Met kinase-IN-2 | 2101241-90-9 | 98.4% | 50 MG
MET kinase-IN-2 is a potent, selective, and orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM. It exhibits antitumor activity.
- Potent and selective MET kinase inhibitor
- Orally bioavailable
- Exhibits antitumor activity
Medchemexpress LLC MET kinase-IN-2 | 2101241-90-9 | 98.4% | 25 MG
MET kinase-IN-2 is a potent, selective, orally bioavailable MET kinase inhibitor with an IC50 of 7.4 nM. It exhibits antitumor activity, making it suitable for research in cancer and related disease areas. This product is for research use only.
- Potent, selective, orally bioavailable MET kinase inhibitor
- Exhibits antitumor activity
- Inhibits various cell lines such as U-87 MG, NIH-H460, HT-29, and MKN-45
- Demonstrates dose-dependent tumor growth inhibition in xenograft models
- Features favorable pharmacokinetic profiles
Medchemexpress LLC Met kinase-IN-2 | 2101241-90-9 | 98.4% | C33H27FN4O4 | 10MG
MET kinase-IN-2 is a potent, selective, orally bioavailable inhibitor of the MET (c-Met/HGFR) receptor tyrosine kinase. It inhibits MET with an IC50 of 7.4 nM, shows antitumor activity in cell-based assays, and has reported activity against several additional kinases and tumor cell lines. Supplied as a solid research chemical for laboratory use.
- Potent MET kinase inhibition (IC50 = 7.4 nM).
- Orally bioavailable, enabling in vivo studies.
- Demonstrated antitumor activity in cell assays.
- Shows additional kinase activity at higher concentrations.
- High-purity solid suitable for research applications.
Medchemexpress LLC Met kinase-IN-2 | 2101241-90-9 | 98.4% | 562.59 g/mol | C33H27FN4O4 | 5 MG
MET kinase-IN-2 is a potent, selective MET (c-Met/HGFR) kinase inhibitor with an enzymatic IC50 of 7.4 nM. The compound shows cellular growth inhibition across multiple cancer cell lines and demonstrates oral antitumor efficacy in xenograft models. It is supplied for preclinical research and is well characterized for purity and molecular properties.
- Potent MET kinase inhibition (IC50 7.4 nM).
- Selective profile with additional activity against AXL, Flt4, KDR, Mer, TEK, and TYRO3.
- Orally bioavailable with demonstrated in vivo antitumor efficacy.
- Documented cellular activity in multiple cancer cell lines.
- High purity and characterized molecular weight and formula.
Chemscene ChemScene | (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride | 250MG | CS-0100156 | 0.98 | 1448189-90-9| MFCD31803433 | 353.88
ChemScene | (2S,4R)-4-Hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide hydrochloride | 250MG | CS-0100156 | 0.98 | 1448189-90-9| MFCD31803433 | 353.88